April 26, 2022 -- It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors, according to Nicole Faust, CEO and chief science officer of Cevec Pharmaceuticals. Faust talked to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in Barcelona, Spain.
Upscaling the production of AAV vectors is "not an easy task," Faust said. She chaired a session on tackling the global shortage of viral vectors on day one of the meeting.
"A lot of people are trying to improve the system," she said. "Another challenge is that the quality of AAV vectors that is going to be produced is going to be really variable."
Faust also highlighted the need for Europe to focus more on opportunities than risks to remain competitive in the market for advanced therapy medicinal products.
Click on the video below to learn more.
Copyright © 2022 scienceboard.net